16.11.2017

New BEAM Alliance Position Paper calls out worldwide stakeholders to support SME-driven innovation and revive the product pipeline fighting antimicrobial resistance

more ...

13.11.2017

AiCuris Announces that its Licensee MSD Received Positive CHMP Opinion for PREVYMIS™ (Letermovir) Recommending Approval in Europe
Positive opinion for EU just after U.S. market authorization

more ...

09.11.2017

AiCuris’ Licensee MSD Received U.S. FDA Approval of PREVYMIS™ (Letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients
First antiviral drug developed from AiCuris’ pipeline to receive market approval

more ...

24.10.2017

AiCuris AIC649 Showed Potential for Functional Cure

more ...

17.10.2017

AiCuris to Present Pre-clinical Data on AIC649 against Chronic Hepatitis B at the AASLD-The Liver Meeting
Data generated in an NIH-funded study being conducted at Georgetown University.

more ...

23.08.2017

AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial (LipP 1) with Topical Pritelivir for the Treatment of recurrent Labial Herpes
The final patient has been treated in the clinical phase 2 efficacy and safety study LipP 1 evaluating topical pritelivir, a small molecule helicase-primase inhibitor, for the treatment of recurrent labial herpes (cold sores)

more ...

01.08.2017

AiCuris Granted Fast Track Designation by U.S. FDA for Oral Pritelivir for Treatment of HSV Infections in Immunocompromised Adults
Fast track is a process designed to facilitate the development, expedite the review and accelerate the approval process of drugs to treat serious conditions and fill an unmet medical need, with the purpose of getting important new drugs to patients sooner

more ...

09.05.2017

AiCuris Initiates U.S. Clinical Phase 2 Trial with Oral Pritelivir
Opening of the first site in its clinical phase 2 study, PRIOH-1

more ...

08.03.2017

AiCuris selects Mercachem as preferred medicinal chemistry partner

more ...

17.01.2017

AiCuris Announces Publication of Phase 2 Clinical Trial Results of Investigational Anti-Herpes Simplex Virus Agent Pritelivir in JAMA
Study results clearly supported pritelivir to be more effective than alacyclovir for suppression of herpes simplex virus (HSV) genital shedding in patients with frequent recurrences

more ...